The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio ® is a ...

The 5th Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) will gather industry leaders in Vösendorf, Austria on ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Shares of 3SBio jumped as much as 52% in Hong Kong, the most on record, extending gains for the third consecutive session.

Chris Toomey, Morgan Stanley managing director of private wealth, said in a latest program on CNBC that he is not bullish on stocks yet and plans to “stay defensive” until a few key issues are ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Merck Animal Health is investing $895 million in a De Soto new facility, which will bring hundreds of jobs. It’s a huge economic investment for the company, and the small town.

Researchers analyzed long-term survival of women diagnosed with low-risk cervical cancer, from 2010 through 2017, who ...

Trump's tariffs are meant to promote investment in domestic manufacturing, but experts told Scripps News the reality of ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

S&P 500 pharma stocks hold firm despite Trump’s drug pricing threat. Is Merck a put-selling opportunity amid headline noise?